Orthofix Medical (NASDAQ:OFIX – Get Free Report) and PROCEPT BioRobotics (NASDAQ:PRCT – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends and risk.
Earnings and Valuation
This table compares Orthofix Medical and PROCEPT BioRobotics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Orthofix Medical | $822.31 million | 0.51 | -$92.19 million | ($1.51) | -6.89 |
| PROCEPT BioRobotics | $322.02 million | 5.11 | -$95.57 million | ($1.82) | -15.90 |
Profitability
This table compares Orthofix Medical and PROCEPT BioRobotics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Orthofix Medical | -7.27% | -13.44% | -7.05% |
| PROCEPT BioRobotics | -31.82% | -27.70% | -20.29% |
Insider & Institutional Ownership
89.8% of Orthofix Medical shares are held by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are held by institutional investors. 2.7% of Orthofix Medical shares are held by company insiders. Comparatively, 6.6% of PROCEPT BioRobotics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Risk & Volatility
Orthofix Medical has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, PROCEPT BioRobotics has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Orthofix Medical and PROCEPT BioRobotics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Orthofix Medical | 1 | 2 | 3 | 0 | 2.33 |
| PROCEPT BioRobotics | 2 | 4 | 8 | 0 | 2.43 |
Orthofix Medical presently has a consensus target price of $16.75, suggesting a potential upside of 60.90%. PROCEPT BioRobotics has a consensus target price of $41.45, suggesting a potential upside of 43.29%. Given Orthofix Medical’s higher probable upside, equities analysts clearly believe Orthofix Medical is more favorable than PROCEPT BioRobotics.
Summary
Orthofix Medical beats PROCEPT BioRobotics on 9 of the 14 factors compared between the two stocks.
About Orthofix Medical
Orthofix Medical Inc. operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations. The Global Orthopedics segment offers products and solutions that allow physicians to treat various orthopedic conditions related to limb reconstruction and deformity correction unrelated to the spine. This segment designs, develops, and markets external and internal fixation orthopedic products that are coupled with enabling digital technologies to serve the complete patient treatment pathway. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, and healthcare providers. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.
About PROCEPT BioRobotics
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
Receive News & Ratings for Orthofix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix Medical and related companies with MarketBeat.com's FREE daily email newsletter.
